Celebrating Success: Major Achievement in COMBACTE-CARE

Read more
combacte-care News Item

172 Patients in EURECA

As of today COMBACTE-CARE’s EURECA study has recruited a total of 172 patients. Currently twenty three sites have been initiated; in eight different countries (one center from Albania , Croatia, Kosovo, Montenegro, seven from Spain, five from Serbia, four from Turkey and three from Romania).

This month’s top enrolling sites are Hospital Universitario Reina Sofia (Dr. De la Torre Cisneros), Spain, with 34 patients, Clinical Center of Serbia (Dr. Biljana Carevic), Serbia, with 34 patients and the Institute of Public Health of Vojvodina (Dr. Gorana Dragovac), Serbia, 29 patients.

EURECA is a very ambitious and challenging study involving 50 sites from 10 countries, aiming at including 2000 patients! All training sessions for participating sites have been done and completed by webcast; a recorded session will be also available for all participants in case they need a refresh some aspects. For those investigators who have not been able to attend the previous web sessions, an additional session will be organized towards the end of November.

Of course the study team in Seville and Antwerp are available for any questions by email and phone.

20/04/2024

EMA recommends Marketing Authorization for ATM-AVI

23/03/2024

Pfizer Receives Positive CHMP Opinion for its Novel Antibiotic Combination for the Treatment of Patients with Multidrug-Resistant Infections and Limited Treatment Options

COMBACTE is proud to announce a significant milestone achieved in COMBACTE-CARE. The European Medicines Agency (EMA) has recommended granting a market...

28/09/2023

REVISIT: A Novel Tool to Treat Highly-Resistant Pathogens?